



## Zebrafish as a Powerful Tool for Drug Discovery 2023

Guest Editor:

**Prof. Dr. Yuhei Nishimura**

Department of Integrative  
Pharmacology, Mie University  
Graduate School of Medicine, Tsu  
514-8507, Japan

Deadline for manuscript  
submissions:

**closed (22 February 2024)**

### Message from the Guest Editor

It has been widely recognized that zebrafish can be powerful tools in the drug discovery field, given advantages

such as high fecundity, ease of drug administration, similarity to mammals in terms of structures and functions

of various tissues, and suitability for the 3Rs. Using genome-editing technologies, genetic abnormalities observed in human diseases can be mimicked in zebrafish to make a disease model. The phenotypes of the disease

model zebrafish can be used to identify novel compounds and/or new indications for old drugs that ameliorate the

abnormal phenotypes of the zebrafish disease models. The toxicity of compounds can also be assessed using

zebrafish. In fact, the International Council for Harmonization has considered including developmental

toxicity testing using zebrafish in their guidelines. Zebrafish can also be integrated to validate the efficacy and toxicities of compounds that are identified as novel therapeutics by other approaches, such as computational drug discovery using big data. In this Special Issue, we invite authors to contribute articles focusing on zebrafish as powerful tools for drug discovery.





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Amélia Pilar Rauter**

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)